Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 59 | 2023 | 2325 | 5.030 |
Why?
|
Hepatitis C, Chronic | 33 | 2022 | 1031 | 4.040 |
Why?
|
End Stage Liver Disease | 16 | 2024 | 353 | 3.690 |
Why?
|
Antiviral Agents | 40 | 2022 | 3061 | 3.690 |
Why?
|
Hepacivirus | 32 | 2022 | 1334 | 3.290 |
Why?
|
Liver Cirrhosis | 47 | 2024 | 1931 | 3.170 |
Why?
|
Hepatitis C | 26 | 2022 | 1579 | 2.880 |
Why?
|
Esophageal and Gastric Varices | 9 | 2023 | 208 | 1.880 |
Why?
|
Ribavirin | 16 | 2019 | 396 | 1.840 |
Why?
|
Hepatorenal Syndrome | 5 | 2023 | 76 | 1.580 |
Why?
|
Carbamates | 7 | 2018 | 192 | 1.570 |
Why?
|
Fluorenes | 7 | 2019 | 156 | 1.020 |
Why?
|
Benzimidazoles | 9 | 2020 | 858 | 1.000 |
Why?
|
Genotype | 18 | 2021 | 12960 | 0.950 |
Why?
|
Gastrointestinal Hemorrhage | 8 | 2023 | 1131 | 0.950 |
Why?
|
Vasoconstrictor Agents | 5 | 2023 | 651 | 0.920 |
Why?
|
Liver Failure | 5 | 2014 | 249 | 0.910 |
Why?
|
Elasticity Imaging Techniques | 8 | 2024 | 388 | 0.900 |
Why?
|
Liver Neoplasms | 16 | 2024 | 4319 | 0.880 |
Why?
|
Hepatitis B | 7 | 2022 | 701 | 0.860 |
Why?
|
Carcinoma, Hepatocellular | 11 | 2024 | 2299 | 0.850 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2023 | 94 | 0.850 |
Why?
|
Uridine Monophosphate | 6 | 2019 | 68 | 0.830 |
Why?
|
Waiting Lists | 11 | 2022 | 763 | 0.780 |
Why?
|
Liver Diseases | 7 | 2024 | 1302 | 0.770 |
Why?
|
Sclerotherapy | 1 | 2019 | 181 | 0.610 |
Why?
|
Tissue Adhesives | 1 | 2019 | 173 | 0.590 |
Why?
|
Liver Diseases, Alcoholic | 2 | 2023 | 156 | 0.570 |
Why?
|
Drug Interactions | 2 | 2021 | 1428 | 0.570 |
Why?
|
Quinoxalines | 6 | 2020 | 297 | 0.520 |
Why?
|
Alcoholism | 3 | 2023 | 1961 | 0.520 |
Why?
|
Postoperative Care | 3 | 2017 | 1479 | 0.520 |
Why?
|
Tissue Donors | 9 | 2022 | 2313 | 0.510 |
Why?
|
Liver | 17 | 2024 | 7509 | 0.510 |
Why?
|
Viral Nonstructural Proteins | 6 | 2018 | 223 | 0.470 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2014 | 113 | 0.460 |
Why?
|
Drug Therapy, Combination | 16 | 2019 | 6498 | 0.430 |
Why?
|
Macrocyclic Compounds | 3 | 2018 | 67 | 0.430 |
Why?
|
Transaminases | 1 | 2013 | 196 | 0.420 |
Why?
|
Preoperative Care | 3 | 2017 | 2256 | 0.420 |
Why?
|
Sulfonamides | 6 | 2020 | 1977 | 0.410 |
Why?
|
Severity of Illness Index | 14 | 2024 | 15840 | 0.400 |
Why?
|
Middle Aged | 91 | 2024 | 220352 | 0.390 |
Why?
|
Lypressin | 4 | 2023 | 26 | 0.380 |
Why?
|
Humans | 153 | 2024 | 760621 | 0.380 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2012 | 301 | 0.380 |
Why?
|
Fatty Liver | 4 | 2024 | 778 | 0.350 |
Why?
|
Immunosuppressive Agents | 3 | 2017 | 4166 | 0.330 |
Why?
|
Varicose Veins | 2 | 2023 | 155 | 0.320 |
Why?
|
Organ Transplantation | 2 | 2017 | 1150 | 0.310 |
Why?
|
Male | 91 | 2024 | 359744 | 0.310 |
Why?
|
Spouses | 1 | 2011 | 279 | 0.310 |
Why?
|
Treatment Outcome | 33 | 2024 | 65017 | 0.310 |
Why?
|
International Normalized Ratio | 2 | 2024 | 386 | 0.310 |
Why?
|
RNA, Viral | 10 | 2018 | 2838 | 0.310 |
Why?
|
Retrospective Studies | 40 | 2024 | 80372 | 0.300 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 107 | 0.300 |
Why?
|
Quality of Life | 6 | 2011 | 13308 | 0.300 |
Why?
|
Fatigue | 3 | 2020 | 1544 | 0.300 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5508 | 0.290 |
Why?
|
Female | 91 | 2024 | 391270 | 0.280 |
Why?
|
Kidney Transplantation | 7 | 2022 | 4215 | 0.280 |
Why?
|
Diagnostic Techniques, Digestive System | 1 | 2007 | 46 | 0.280 |
Why?
|
Drug Administration Schedule | 8 | 2017 | 4899 | 0.270 |
Why?
|
Florida | 3 | 2013 | 430 | 0.270 |
Why?
|
Social Support | 2 | 2013 | 2145 | 0.270 |
Why?
|
Medication Adherence | 2 | 2017 | 2165 | 0.260 |
Why?
|
Sirolimus | 2 | 2012 | 1547 | 0.260 |
Why?
|
Microspheres | 3 | 2024 | 787 | 0.260 |
Why?
|
Adaptation, Psychological | 2 | 2013 | 2628 | 0.250 |
Why?
|
Multivariate Analysis | 8 | 2017 | 12159 | 0.240 |
Why?
|
Drug Resistance, Viral | 4 | 2017 | 859 | 0.240 |
Why?
|
Biliary Tract Diseases | 1 | 2005 | 157 | 0.230 |
Why?
|
Gallbladder Diseases | 1 | 2005 | 137 | 0.230 |
Why?
|
Venous Thrombosis | 2 | 2023 | 1299 | 0.220 |
Why?
|
Aged | 44 | 2024 | 169152 | 0.220 |
Why?
|
Hepatic Artery | 3 | 2018 | 230 | 0.220 |
Why?
|
Adult | 59 | 2024 | 219994 | 0.220 |
Why?
|
Primary Graft Dysfunction | 3 | 2013 | 111 | 0.220 |
Why?
|
Ceftriaxone | 1 | 2024 | 176 | 0.210 |
Why?
|
Drug Combinations | 6 | 2020 | 2025 | 0.210 |
Why?
|
Recurrence | 8 | 2017 | 8482 | 0.210 |
Why?
|
Hepatitis B, Chronic | 2 | 2022 | 403 | 0.200 |
Why?
|
Health Status | 2 | 2013 | 4081 | 0.200 |
Why?
|
Diffusion of Innovation | 1 | 2007 | 730 | 0.200 |
Why?
|
B-Lymphocyte Subsets | 1 | 2003 | 241 | 0.200 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2022 | 127 | 0.200 |
Why?
|
Ascites | 3 | 2023 | 338 | 0.190 |
Why?
|
Interferon Type I | 1 | 2005 | 559 | 0.190 |
Why?
|
Pyrrolidines | 2 | 2020 | 340 | 0.190 |
Why?
|
Sodium | 2 | 2024 | 1594 | 0.190 |
Why?
|
Logistic Models | 6 | 2021 | 13314 | 0.180 |
Why?
|
Cavernous Sinus | 1 | 2001 | 123 | 0.180 |
Why?
|
Creatinine | 2 | 2024 | 1903 | 0.180 |
Why?
|
Hepatic Encephalopathy | 2 | 2018 | 144 | 0.180 |
Why?
|
Hepatitis B Antibodies | 1 | 2000 | 157 | 0.170 |
Why?
|
Pilot Projects | 5 | 2024 | 8555 | 0.170 |
Why?
|
Organ Preservation Solutions | 1 | 2000 | 100 | 0.170 |
Why?
|
Hepatitis, Alcoholic | 1 | 2021 | 109 | 0.170 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 167 | 0.170 |
Why?
|
Recovery of Function | 2 | 2012 | 2985 | 0.170 |
Why?
|
Time Factors | 12 | 2017 | 40165 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2016 | 1548 | 0.170 |
Why?
|
Graft Rejection | 4 | 2017 | 4426 | 0.170 |
Why?
|
Prognosis | 14 | 2023 | 29658 | 0.160 |
Why?
|
Mental Health | 1 | 2013 | 3213 | 0.160 |
Why?
|
Kidney | 3 | 2022 | 7064 | 0.160 |
Why?
|
Alanine Transaminase | 2 | 2015 | 606 | 0.160 |
Why?
|
North America | 1 | 2023 | 1284 | 0.160 |
Why?
|
Viremia | 2 | 2023 | 707 | 0.160 |
Why?
|
Caregivers | 1 | 2011 | 2224 | 0.160 |
Why?
|
Interferon-alpha | 2 | 2014 | 918 | 0.160 |
Why?
|
United States | 18 | 2024 | 72461 | 0.160 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4902 | 0.160 |
Why?
|
Viral Load | 5 | 2017 | 3322 | 0.160 |
Why?
|
Aminoisobutyric Acids | 4 | 2020 | 39 | 0.150 |
Why?
|
Respiratory Insufficiency | 3 | 2022 | 1231 | 0.150 |
Why?
|
Hypertension, Portal | 2 | 2017 | 226 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2001 | 514 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 530 | 0.150 |
Why?
|
Benzofurans | 1 | 2018 | 142 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 1 | 2011 | 3164 | 0.140 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 1189 | 0.140 |
Why?
|
Portal Pressure | 1 | 2017 | 60 | 0.140 |
Why?
|
New Zealand | 2 | 2014 | 355 | 0.140 |
Why?
|
Hepatic Veins | 1 | 2017 | 112 | 0.140 |
Why?
|
Risk Assessment | 7 | 2021 | 24123 | 0.140 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 550 | 0.140 |
Why?
|
Endoscopy, Digestive System | 1 | 2019 | 351 | 0.140 |
Why?
|
Balloon Occlusion | 1 | 2017 | 127 | 0.140 |
Why?
|
Hepatitis C Antibodies | 1 | 2016 | 145 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 831 | 0.140 |
Why?
|
Cyclopropanes | 4 | 2020 | 431 | 0.140 |
Why?
|
Leucine | 4 | 2020 | 547 | 0.140 |
Why?
|
Interferons | 2 | 2017 | 705 | 0.130 |
Why?
|
Lactams, Macrocyclic | 4 | 2020 | 315 | 0.130 |
Why?
|
Proline | 4 | 2020 | 457 | 0.130 |
Why?
|
Lamivudine | 2 | 2010 | 363 | 0.130 |
Why?
|
Hepatitis, Chronic | 2 | 2011 | 52 | 0.130 |
Why?
|
Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
Feasibility Studies | 2 | 2024 | 5201 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2023 | 1341 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 602 | 0.130 |
Why?
|
Cystic Fibrosis | 1 | 2005 | 1274 | 0.130 |
Why?
|
Ultrasonography, Interventional | 1 | 2024 | 1502 | 0.130 |
Why?
|
Antigens, CD | 2 | 2003 | 4000 | 0.130 |
Why?
|
Predictive Value of Tests | 9 | 2024 | 15289 | 0.130 |
Why?
|
Albumins | 3 | 2023 | 575 | 0.130 |
Why?
|
Stress, Psychological | 1 | 2011 | 4446 | 0.130 |
Why?
|
Mood Disorders | 2 | 2013 | 1124 | 0.130 |
Why?
|
Neurotransmitter Agents | 1 | 2019 | 663 | 0.130 |
Why?
|
Cohort Studies | 16 | 2021 | 41335 | 0.130 |
Why?
|
Ammonia | 1 | 2016 | 236 | 0.120 |
Why?
|
Death | 2 | 2011 | 678 | 0.120 |
Why?
|
Graft Occlusion, Vascular | 1 | 2018 | 560 | 0.120 |
Why?
|
Cytokines | 3 | 2019 | 7343 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 1 | 2017 | 177 | 0.120 |
Why?
|
Graft Survival | 6 | 2018 | 3794 | 0.120 |
Why?
|
Cell Separation | 1 | 2000 | 1720 | 0.120 |
Why?
|
Patient Selection | 4 | 2018 | 4283 | 0.120 |
Why?
|
Blood Chemical Analysis | 2 | 2015 | 437 | 0.120 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 597 | 0.120 |
Why?
|
Apolipoproteins | 1 | 2016 | 320 | 0.120 |
Why?
|
Portal Vein | 3 | 2023 | 429 | 0.120 |
Why?
|
Bronchial Neoplasms | 1 | 2014 | 110 | 0.110 |
Why?
|
Nephrectomy | 1 | 2020 | 1016 | 0.110 |
Why?
|
Transplants | 1 | 2016 | 206 | 0.110 |
Why?
|
HIV Infections | 6 | 2017 | 17165 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2015 | 238 | 0.110 |
Why?
|
Lipase | 1 | 2016 | 324 | 0.110 |
Why?
|
Aspartate Aminotransferases | 1 | 2014 | 416 | 0.110 |
Why?
|
Risk Factors | 16 | 2022 | 74359 | 0.110 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 695 | 0.110 |
Why?
|
Membrane Proteins | 2 | 2016 | 7850 | 0.110 |
Why?
|
Postoperative Complications | 6 | 2017 | 15697 | 0.110 |
Why?
|
Glomerulonephritis, IGA | 1 | 2013 | 62 | 0.100 |
Why?
|
Lymphocytes | 1 | 2000 | 2611 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 667 | 0.100 |
Why?
|
BK Virus | 1 | 2013 | 123 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1180 | 0.100 |
Why?
|
Activities of Daily Living | 2 | 2011 | 2417 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2024 | 3839 | 0.100 |
Why?
|
Thrombosis | 3 | 2022 | 3052 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 575 | 0.100 |
Why?
|
Biopsy | 6 | 2017 | 6771 | 0.100 |
Why?
|
Fibrosis | 3 | 2024 | 2042 | 0.090 |
Why?
|
Hepatitis B virus | 2 | 2012 | 522 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2016 | 551 | 0.090 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3465 | 0.090 |
Why?
|
Interleukins | 1 | 2016 | 785 | 0.090 |
Why?
|
Cold Ischemia | 1 | 2011 | 67 | 0.090 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7806 | 0.090 |
Why?
|
Polyomavirus Infections | 1 | 2013 | 194 | 0.090 |
Why?
|
Prevalence | 3 | 2021 | 15687 | 0.090 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 1413 | 0.090 |
Why?
|
Aged, 80 and over | 9 | 2020 | 58995 | 0.090 |
Why?
|
Health Personnel | 2 | 2023 | 3310 | 0.090 |
Why?
|
Platelet Count | 1 | 2013 | 777 | 0.090 |
Why?
|
Tumor Virus Infections | 1 | 2013 | 438 | 0.090 |
Why?
|
Renal Replacement Therapy | 2 | 2023 | 281 | 0.090 |
Why?
|
Disease Management | 2 | 2020 | 2514 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2020 | 4312 | 0.090 |
Why?
|
Single-Blind Method | 1 | 2013 | 1578 | 0.090 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4810 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6544 | 0.090 |
Why?
|
Young Adult | 11 | 2022 | 58741 | 0.080 |
Why?
|
Keratin-18 | 1 | 2009 | 38 | 0.080 |
Why?
|
Abdomen | 1 | 2015 | 1130 | 0.080 |
Why?
|
Polytetrafluoroethylene | 1 | 2010 | 245 | 0.080 |
Why?
|
Pulmonary Veins | 1 | 2015 | 745 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3880 | 0.080 |
Why?
|
Affective Symptoms | 1 | 2011 | 416 | 0.080 |
Why?
|
Postoperative Period | 1 | 2013 | 1818 | 0.080 |
Why?
|
Attitude to Death | 1 | 2011 | 400 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1386 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12293 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 2882 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2016 | 9185 | 0.070 |
Why?
|
Thrombectomy | 2 | 2023 | 708 | 0.070 |
Why?
|
Europe | 1 | 2014 | 3441 | 0.070 |
Why?
|
Primary Health Care | 2 | 2021 | 4647 | 0.070 |
Why?
|
Ventilator Weaning | 1 | 2008 | 161 | 0.070 |
Why?
|
Th1 Cells | 2 | 2002 | 1032 | 0.070 |
Why?
|
Linear Models | 2 | 2021 | 5877 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 1722 | 0.070 |
Why?
|
Sensitivity and Specificity | 5 | 2015 | 14660 | 0.070 |
Why?
|
Cyclosporine | 1 | 2009 | 777 | 0.070 |
Why?
|
Methylene Blue | 1 | 2007 | 157 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 936 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1066 | 0.070 |
Why?
|
Personal Satisfaction | 1 | 2011 | 643 | 0.070 |
Why?
|
B-Lymphocytes | 1 | 2000 | 4742 | 0.070 |
Why?
|
Tissue and Organ Procurement | 3 | 2012 | 944 | 0.070 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1921 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5351 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39261 | 0.070 |
Why?
|
Survival Rate | 6 | 2021 | 12808 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2001 | 4024 | 0.070 |
Why?
|
Immunoglobulins | 2 | 2010 | 859 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3527 | 0.060 |
Why?
|
Liver Function Tests | 2 | 2005 | 524 | 0.060 |
Why?
|
Tacrolimus | 1 | 2009 | 733 | 0.060 |
Why?
|
Patient Satisfaction | 2 | 2023 | 3448 | 0.060 |
Why?
|
Fatal Outcome | 3 | 2014 | 1832 | 0.060 |
Why?
|
Intubation | 1 | 2005 | 139 | 0.060 |
Why?
|
SEER Program | 2 | 2021 | 1530 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5649 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10344 | 0.060 |
Why?
|
Viral Envelope Proteins | 2 | 2013 | 638 | 0.060 |
Why?
|
Information Storage and Retrieval | 2 | 2021 | 822 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8056 | 0.060 |
Why?
|
Coronary Artery Disease | 2 | 2021 | 6659 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1915 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3218 | 0.060 |
Why?
|
Biliary Tract | 1 | 2005 | 135 | 0.060 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6538 | 0.060 |
Why?
|
Survival Analysis | 4 | 2020 | 10182 | 0.060 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2002 | 321 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2015 | 20509 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2007 | 908 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5697 | 0.060 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 133 | 0.060 |
Why?
|
Genes, MHC Class I | 1 | 2004 | 240 | 0.060 |
Why?
|
Boston | 3 | 2012 | 9280 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20080 | 0.060 |
Why?
|
Gallbladder | 1 | 2005 | 305 | 0.060 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 2512 | 0.050 |
Why?
|
Genes, MHC Class II | 1 | 2004 | 451 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2002 | 2203 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4878 | 0.050 |
Why?
|
Ontario | 1 | 2024 | 404 | 0.050 |
Why?
|
Adolescent | 8 | 2021 | 87810 | 0.050 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2022 | 84 | 0.050 |
Why?
|
Reoperation | 3 | 2018 | 4291 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 169 | 0.050 |
Why?
|
Attitude to Health | 1 | 2011 | 2029 | 0.050 |
Why?
|
Terminal Care | 1 | 2014 | 1758 | 0.050 |
Why?
|
K562 Cells | 2 | 2002 | 640 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5889 | 0.050 |
Why?
|
Tissue and Organ Harvesting | 1 | 2005 | 377 | 0.050 |
Why?
|
Endoscopy | 3 | 2017 | 1838 | 0.050 |
Why?
|
Hypotension | 1 | 2008 | 883 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 446 | 0.050 |
Why?
|
Complement Pathway, Classical | 1 | 2001 | 92 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6957 | 0.050 |
Why?
|
Immunophenotyping | 3 | 2002 | 1871 | 0.050 |
Why?
|
Viral Core Proteins | 1 | 2002 | 161 | 0.050 |
Why?
|
Suction | 1 | 2022 | 263 | 0.050 |
Why?
|
Diffusion Tensor Imaging | 1 | 2012 | 2385 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9716 | 0.050 |
Why?
|
Pentanoic Acids | 1 | 2020 | 19 | 0.050 |
Why?
|
Complement C4 | 1 | 2001 | 244 | 0.050 |
Why?
|
Raffinose | 1 | 2000 | 53 | 0.050 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 2180 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 25942 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4013 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2021 | 2234 | 0.050 |
Why?
|
Massachusetts | 1 | 2013 | 8803 | 0.050 |
Why?
|
Device Removal | 1 | 2005 | 636 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1630 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2004 | 4353 | 0.040 |
Why?
|
Blood Component Transfusion | 1 | 2021 | 141 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5961 | 0.040 |
Why?
|
Donor Selection | 1 | 2022 | 228 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2021 | 12427 | 0.040 |
Why?
|
Neutropenia | 1 | 2005 | 884 | 0.040 |
Why?
|
Prospective Studies | 6 | 2024 | 54303 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 296 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2021 | 388 | 0.040 |
Why?
|
Morbidity | 1 | 2005 | 1765 | 0.040 |
Why?
|
Alanine | 1 | 2022 | 606 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 698 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2002 | 587 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 617 | 0.040 |
Why?
|
Palliative Care | 1 | 2014 | 3607 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 36290 | 0.040 |
Why?
|
Rheumatoid Factor | 1 | 2000 | 185 | 0.040 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 471 | 0.040 |
Why?
|
Medicare | 3 | 2023 | 6786 | 0.040 |
Why?
|
Allopurinol | 1 | 2000 | 198 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4550 | 0.040 |
Why?
|
Living Donors | 1 | 2023 | 636 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2000 | 445 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2023 | 755 | 0.040 |
Why?
|
Constriction, Pathologic | 2 | 2018 | 1098 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3202 | 0.040 |
Why?
|
Necrosis | 1 | 2022 | 1612 | 0.040 |
Why?
|
Acute Disease | 2 | 2017 | 7269 | 0.040 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 824 | 0.040 |
Why?
|
Angiography | 1 | 2023 | 1605 | 0.040 |
Why?
|
Glutathione | 1 | 2000 | 582 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13630 | 0.040 |
Why?
|
Plasma | 1 | 2021 | 584 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6068 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2014 | 3736 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 11847 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2005 | 1174 | 0.040 |
Why?
|
Angiography, Digital Subtraction | 1 | 2018 | 334 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8552 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4371 | 0.040 |
Why?
|
Osteolysis | 1 | 1999 | 274 | 0.040 |
Why?
|
Mesenteric Veins | 1 | 1997 | 85 | 0.030 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 1999 | 364 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2012 | 22053 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2021 | 499 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16546 | 0.030 |
Why?
|
Lipoproteins | 1 | 2021 | 882 | 0.030 |
Why?
|
Antigens, CD19 | 1 | 2000 | 424 | 0.030 |
Why?
|
Endopeptidases | 1 | 2000 | 772 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2000 | 1130 | 0.030 |
Why?
|
Israel | 1 | 2019 | 722 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 4107 | 0.030 |
Why?
|
Pruritus | 1 | 2020 | 377 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 1411 | 0.030 |
Why?
|
Pain | 1 | 2011 | 5066 | 0.030 |
Why?
|
HLA-DR Antigens | 3 | 2004 | 630 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15789 | 0.030 |
Why?
|
Serine Proteases | 1 | 2016 | 50 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2002 | 1355 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2023 | 2435 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6180 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2002 | 5870 | 0.030 |
Why?
|
Antibody Formation | 1 | 2000 | 1400 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2000 | 1446 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1511 | 0.030 |
Why?
|
Body Mass Index | 2 | 2010 | 12914 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2024 | 1204 | 0.030 |
Why?
|
Alleles | 2 | 2004 | 6898 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2197 | 0.030 |
Why?
|
Vascular Patency | 1 | 2018 | 901 | 0.030 |
Why?
|
Interferon-gamma | 2 | 2002 | 3157 | 0.030 |
Why?
|
Software | 2 | 2024 | 4419 | 0.030 |
Why?
|
Adenosine | 1 | 2000 | 834 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 422 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11152 | 0.030 |
Why?
|
Patient Compliance | 1 | 2005 | 2688 | 0.030 |
Why?
|
HIV | 2 | 2014 | 1579 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2002 | 1998 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2002 | 1810 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
Ischemia | 1 | 2023 | 1893 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1725 | 0.030 |
Why?
|
Gastroenterology | 1 | 2000 | 571 | 0.030 |
Why?
|
Cholestasis | 1 | 2017 | 377 | 0.030 |
Why?
|
Drug Approval | 1 | 2021 | 816 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15757 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2002 | 2536 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2017 | 5425 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2017 | 755 | 0.030 |
Why?
|
Spain | 1 | 2014 | 488 | 0.030 |
Why?
|
Models, Economic | 1 | 2017 | 719 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1958 | 0.030 |
Why?
|
Advance Directives | 1 | 2014 | 248 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 861 | 0.030 |
Why?
|
Heart Diseases | 1 | 2005 | 2809 | 0.030 |
Why?
|
Cholesterol | 1 | 2021 | 2924 | 0.030 |
Why?
|
Vaccination | 1 | 2004 | 3361 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1933 | 0.030 |
Why?
|
Disease Progression | 3 | 2016 | 13502 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2017 | 11071 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2648 | 0.020 |
Why?
|
Headache | 1 | 2020 | 1249 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 22072 | 0.020 |
Why?
|
Hemorrhage | 1 | 2024 | 3600 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2932 | 0.020 |
Why?
|
Oligopeptides | 1 | 2016 | 1187 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6238 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2192 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2013 | 226 | 0.020 |
Why?
|
Child | 4 | 2023 | 79806 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3143 | 0.020 |
Why?
|
Cell Survival | 1 | 2000 | 5797 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1724 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2821 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2932 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 1501 | 0.020 |
Why?
|
Bone Marrow | 1 | 2000 | 2912 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2021 | 4563 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9287 | 0.020 |
Why?
|
Databases, Factual | 2 | 2020 | 8035 | 0.020 |
Why?
|
Echocardiography | 1 | 2022 | 4981 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7475 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 151 | 0.020 |
Why?
|
Bronchoscopy | 1 | 2014 | 911 | 0.020 |
Why?
|
Computer Simulation | 2 | 2012 | 6218 | 0.020 |
Why?
|
Anisotropy | 1 | 2012 | 1278 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4035 | 0.020 |
Why?
|
Hepatitis | 1 | 2010 | 230 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5523 | 0.020 |
Why?
|
Atrophy | 1 | 2013 | 1627 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2254 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3387 | 0.020 |
Why?
|
Interleukin-10 | 2 | 2004 | 1175 | 0.020 |
Why?
|
Colonoscopy | 1 | 2015 | 1387 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2007 | 133 | 0.020 |
Why?
|
Genetic Variation | 1 | 2002 | 6551 | 0.020 |
Why?
|
Age Factors | 3 | 2009 | 18416 | 0.020 |
Why?
|
Lectins | 1 | 2009 | 484 | 0.020 |
Why?
|
DNA, Viral | 1 | 2014 | 2194 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2001 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12766 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4122 | 0.020 |
Why?
|
Adipokines | 1 | 2009 | 311 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1257 | 0.020 |
Why?
|
Renal Circulation | 1 | 2007 | 291 | 0.020 |
Why?
|
Stents | 1 | 2018 | 3314 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2852 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2010 | 557 | 0.020 |
Why?
|
Viruses | 1 | 2010 | 376 | 0.020 |
Why?
|
Radiography | 2 | 2009 | 6965 | 0.020 |
Why?
|
Insulin | 1 | 2000 | 6597 | 0.020 |
Why?
|
Hyaluronic Acid | 1 | 2009 | 482 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6828 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3905 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12965 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 1997 | 2250 | 0.020 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.020 |
Why?
|
Pancreas Transplantation | 1 | 2005 | 196 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2000 | 18957 | 0.010 |
Why?
|
JC Virus | 1 | 2005 | 87 | 0.010 |
Why?
|
Rho(D) Immune Globulin | 1 | 2004 | 34 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10827 | 0.010 |
Why?
|
Resource Allocation | 1 | 2007 | 349 | 0.010 |
Why?
|
Cardiac Output | 1 | 2007 | 838 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 2011 | 1023 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10551 | 0.010 |
Why?
|
HLA-A Antigens | 1 | 2004 | 225 | 0.010 |
Why?
|
Algorithms | 1 | 2024 | 13981 | 0.010 |
Why?
|
Virus Diseases | 1 | 2010 | 720 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2471 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2290 | 0.010 |
Why?
|
Contrast Media | 1 | 2017 | 5305 | 0.010 |
Why?
|
Registries | 1 | 2020 | 8469 | 0.010 |
Why?
|
Cause of Death | 1 | 2014 | 3725 | 0.010 |
Why?
|
Receptors, KIR2DL1 | 1 | 2002 | 15 | 0.010 |
Why?
|
Receptors, KIR2DL3 | 1 | 2002 | 17 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2002 | 30 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2002 | 42 | 0.010 |
Why?
|
Mast-Cell Sarcoma | 1 | 2002 | 46 | 0.010 |
Why?
|
Receptors, KIR3DL1 | 1 | 2002 | 27 | 0.010 |
Why?
|
Drug Contamination | 1 | 2004 | 152 | 0.010 |
Why?
|
Mental Disorders | 2 | 2017 | 6796 | 0.010 |
Why?
|
Brain | 2 | 2012 | 26951 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8624 | 0.010 |
Why?
|
Receptors, KIR | 1 | 2002 | 113 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3696 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2634 | 0.010 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2001 | 92 | 0.010 |
Why?
|
Blood Pressure | 2 | 2008 | 8525 | 0.010 |
Why?
|
Electroencephalography | 1 | 2017 | 6189 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12531 | 0.010 |
Why?
|
Interleukin-5 | 1 | 2002 | 268 | 0.010 |
Why?
|
Glycoproteins | 1 | 2009 | 2208 | 0.010 |
Why?
|
Critical Illness | 1 | 2014 | 2709 | 0.010 |
Why?
|
ROC Curve | 1 | 2009 | 3568 | 0.010 |
Why?
|
Edetic Acid | 1 | 2001 | 282 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 2002 | 228 | 0.010 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1328 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 450 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2000 | 211 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2005 | 857 | 0.010 |
Why?
|
Incidence | 2 | 2008 | 21392 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 1351 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 801 | 0.010 |
Why?
|
Cell Count | 1 | 2002 | 1835 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2000 | 717 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 2000 | 465 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 1628 | 0.010 |
Why?
|
Cold Temperature | 1 | 2001 | 780 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2696 | 0.010 |
Why?
|
Mice | 2 | 2002 | 81208 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6465 | 0.010 |
Why?
|
Phylogeny | 1 | 2002 | 2775 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6131 | 0.010 |
Why?
|
Monocytes | 1 | 2004 | 2575 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2002 | 1885 | 0.010 |
Why?
|
Haplotypes | 1 | 2000 | 2764 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14495 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 1997 | 983 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4925 | 0.010 |
Why?
|
Animals | 2 | 2002 | 167963 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 13451 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17624 | 0.010 |
Why?
|
Child, Preschool | 1 | 2012 | 42063 | 0.010 |
Why?
|
Bone and Bones | 1 | 1999 | 2560 | 0.000 |
Why?
|
Inflammation | 1 | 2007 | 10756 | 0.000 |
Why?
|
Bone Density | 1 | 1999 | 3534 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 2002 | 6315 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2002 | 6853 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2000 | 11481 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2000 | 17790 | 0.000 |
Why?
|